Spots Global Cancer Trial Database for Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Study Description

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.

Detailed Description: Efficacy of the combined regimen is evaluated primarily by objective remission rate, including complete remission, unverified complete remission and partial remission, also by duration of remission, progression free survival, and overall survival. Safety is accessed by: 1. The type, incidence, severity of incidents related to the use of the regimen. 2. Laboratory abnormalities, including the type, incidence, severity, relationship with the use of the regimen. 3. Incidence of level 3-4 incidents and laboratory abnormalities.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial